| Document |
Document Title |
|
WO/2021/080511A1 |
The present invention relates, in general terms, to methods of borylation and uses thereof. In particular, the present invention provides a method of borylating an alkene compound by contacting the compound with a boron compound, a Fe pr...
|
|
WO/2021/079984A1 |
The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b...
|
|
WO/2021/074275A1 |
The invention relates to photochromic complexes of lanthanide (III) ions of chemical formula (I) and their use in different fields of application, in particular in security systems for identification, authentication and/or protection aga...
|
|
WO/2021/073385A1 |
Provided is an organic compound, having a structure of the following formula (1). Rings A, B, C, D, and E each independently represent an aromatic ring or a heteroaromatic ring, and two adjacent rings can be fused to form a five-membered...
|
|
WO/2021/075417A1 |
The purpose of the present invention is to provide a curing catalyst which has high safety and a practical curing rate, while exhibiting excellent stability in a moisture curable composition. The present invention provides a curing cat...
|
|
WO/2021/073456A1 |
Provided are a class of macrocyclic and cage-like molecules based on a biphenylarene and derivative compounds, a synthesis method therefor and the use thereof. A series of new macrocycles and molecular cages are obtained in a high yield ...
|
|
WO/2021/071932A1 |
The present application relates to methods for treatment of bacteria and viruses with C2-C7 alkyl boronic acids to reduce growth and virulence.
|
|
WO/2021/071345A2 |
The present invention relates to a novel polycyclic compound employed in an organic layer of an organoelectro luminescent device, wherein the organoelectro luminescent device employing the compound according to the present invention has ...
|
|
WO/2021/068828A1 |
The invention provides a chemiluminescence substrate having high luminescence intensity, a long wavelength, and good stability, and a preparation method therefor and an application thereof. The chemiluminescence substrate has a structure...
|
|
WO/2021/069685A1 |
The invention relates to a new fluorescent analogue of vancomycin and to the use of same to detect gram+ bacteria, in particular in a rapid diagnostic method for identifying the presence of gram+ bacteria in vivo, for example infectious ...
|
|
WO/2021/066742A1 |
Disclosed herein is a polycrystalline metal-organic framework membrane comprising a substrate material having a surface and a polycrystalline metal-organic framework attached to the surface of the substrate material, wherein the polycrys...
|
|
WO/2021/064199A1 |
The present invention relates to novel alkynyl aminoboranes, wherein the process for preparing same comprises bringing into contact in a single synthesis step a terminal alkyne, an aminoborane and an organomagnesium, in particular a Grig...
|
|
WO/2021/063967A1 |
The present invention relates to a compound of the formula (I) wherein Ar represents a phenyl or a 6-membered heteroaryl group, R1 and R2 represent independently a hydrogen atom or a deuterium atom, R3 represents (1) a -COR4 group, (2) a...
|
|
WO/2021/064205A1 |
The present invention relates to a method for preparing alkenyl aminoboranes and their derivatives, and uses thereof. The method for preparing alkenyl aminoboranes comprises contacting, preferably in a single synthesis step, a terminal a...
|
|
WO/2021/059946A1 |
The present invention provides: an optically anisotropic film having greater refractive index anisotropy and exhibiting reverse wavelength dispersibility; a polarizing plate; an image display device; a composition; and a compound. The op...
|
|
WO/2021/062204A1 |
A phosphorous compound such as STMP is used as a cross-linking agent while making a starch nanoparticle with a bisphosphonate drug in an emulsion process. Negative charge of the nanoparticle is optionally reduced or reversed by adding ca...
|
|
WO/2021/058443A1 |
The invention provides fluorescent probes having the general formula (I) wherein X, Y, L and R1 to R4 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compou...
|
|
WO/2021/061823A1 |
The present disclosure describes novel compounds, or their pharmaceutically acceptable salts, pharmaceutical compositions containing them, and their medical uses. The compounds of the disclosure have activity as Janus kinase (JAK) inhibi...
|
|
WO/2021/058406A1 |
The present invention relates to compounds of the formula (1) which are suitable for use in electronic devices, in particular organic electroluminescent devices, and to electronic devices which comprise these compounds.
|
|
WO/2021/055752A1 |
The disclosure relates to benzoxaborole containing polymers and to methods of using the same to treat metabolic and gastrointestinal disorders.
|
|
WO/2021/055759A1 |
The disclosure relates to cationic polymers functionalized with substituted phenylboronic acid groups and to methods of using the same to treat metabolic and gastrointestinal disorders.
|
|
WO/2021/049600A1 |
Provided is a pharmaceutical composition that is effective against various β-lactamase-producing bacteria. The present invention provides a pharmaceutical composition characterized by combining: a compound indicated by formula (I) or ...
|
|
WO/2021/049537A1 |
The present invention provides: a three-dimensional control catalyst suitable for the polymerization of a wide range of monomers and used in radical polymerization whereby polymerization that controls both molecular weight (molecular wei...
|
|
WO/2021/049889A1 |
The present specification provides a compound represented by chemical formula 1, and an organic light-emitting device comprising same.
|
|
WO/2021/048044A1 |
The present invention relates to an electronic component comprising a cerium IV complex, a doped semi-conductor matrix material comprising the cerium IV complex and at least one electron donor, the use of the cerium IV complex, especiall...
|
|
WO/2021/049520A1 |
Provided is an injection for boron neutron capture therapy. An injection that is for boron neutron capture therapy and is to be administered by drip infusion. The injection contains p-boronophenylalanine or a pharmacologically acceptable...
|
|
WO/2021/043187A1 |
Provided is a method for preparing a boron salt of a dipeptide of valine-proline. The method uses pyrrolidine boric acid protected by an R1 group and valine protected by an R4 group as the initial raw materials, and avoids the problem of...
|
|
WO/2021/045207A1 |
The present invention relates to a production method for a highly reactive intermediate. The production method includes: preparing an electron-accepting active compound (1); preparing a piezoelectric material (3); and applying mechanical...
|
|
WO/2021/037278A1 |
Provided are an A-D-A conjugated molecule, a preparation method therefor, an organic solar cell, and the use of the A-D-A conjugated molecule in an organic solar cell. The A-D-A conjugated molecule has the following general structure: (I...
|
|
WO/2021/040455A1 |
The present invention relates to a metal-organic framework (MOF) having a three dimensional porous structure and being represented by the chemical formula of [Al8(OH)a(BTC)b(IPA)c(L)d], a preparation method therefor, and a use thereof as...
|
|
WO/2021/036515A1 |
Provided is a method for synthesizing an alkenyl borate compound, the method comprising: dissolving an alkene compound and a borane compound in a solvent to obtain a mixed solution; adding a zirconium catalyst to the mixed solution; in a...
|
|
WO/2021/033530A1 |
This method for producing a radioactive metal complex comprises a step for reacting a radioactive metal with DOTA or a ligand, which is a derivative of DOTA, in a reaction solution to form a radioactive metal complex. The reaction soluti...
|
|
WO/2021/032088A1 |
The present invention relates to a method for preparing a L-erythrobiopterin compound. The L-erythrobiopterin compound has a structure represented by formula (I), and the L-erythrobiopterin compound represented by formula (I) is mainly p...
|
|
WO/2021/025903A1 |
The present disclosure is related to activator compounds represented by: [Ar(E 1 R 1 R 2 H)x(E 2 R 3 R 4)y][QR 5 R 6 R 7 R 8]z In the formula Ar is a C6-C30 aromatic hydrocarbyl group, provided that if Ar is a multicyclic ring, then each...
|
|
WO/2021/026495A1 |
Embodiments of the present disclosure pertain to methods of treating or preventing Alzheimer's disease or symptoms of Alzheimer's disease in a subject by administering to the subject an active agent that includes an adenovirus-36 E4orf1 ...
|
|
WO/2021/021932A1 |
The present invention relates to methods of preparing benzoxaboroles. Benzoxaborole compounds have shown promise as antimicrobial agents, especially against fungal pathogens. The invention also relates to compositions of acyclic alkoxy b...
|
|
WO/2021/020285A1 |
The purpose of the present invention is to provide a cyclic azine compound that exhibits both excellent driving voltage characteristics and excellent current efficiency characteristics. This cyclic azine compound has a specific structu...
|
|
WO/2021/017274A1 |
The present invention provides a thermally activated delayed fluorescent molecular material and a synthesis method therefor, and an organic electroluminescent device. Boron-nitrogen containing thermally activated delayed fluorescent mole...
|
|
WO/2021/021634A1 |
Compositions for delivering nucleic acids to cells or tissue microenvironments are provided. In one embodiment, the compositions are lipid nanoparticle compositions formulated to have reduced splenic and hepatic clearance. It has been di...
|
|
WO/2021/020928A2 |
The present specification relates to a polycyclic compound and an organic light-emitting element comprising same.
|
|
WO/2021/020929A1 |
The present specification relates to a compound of chemical formula 1 and an organic light emitting device comprising same.
|
|
WO/2021/020931A1 |
The present specification relates to a compound represented by chemical formula 1, and an organic light emitting device comprising same. In chemical formula 1: A and B may be the same or different, each can be an independently substitute...
|
|
WO/2021/015841A1 |
Provided herein are boron-containing compounds, pharmaceutical compositions comprising such compounds, and methods of using such compounds to treat diseases or disorders.
|
|
WO/2021/013986A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of formula I wherein RI, RII, RIII and RIV are independently from...
|
|
WO/2021/013996A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of formula (I) wherein RI, RII, RIII and RIV are independently fr...
|
|
WO/2021/015020A1 |
A pyrromethene-boron complex according to an embodiment of the present invention is a compound represented by the following formula (1) and having a molecular weight of at least 1,000, wherein at least two of the R1 to R6 in the formula ...
|
|
WO/2021/014023A1 |
The present invention relates to a an organic electroluminescent device comprising at least one light-emitting layer B comprising at least one host material HB, at least one thermally activated delayed fluorescence (TADF) material EB, an...
|
|
WO/2021/013993A1 |
The invention relates to an organic molecule, in particular for the application in optoelectronic devices. According to the invention, the organic molecule has a structure of Formula (I) wherein RI, RII, RIII and RIV is independently fro...
|
|
WO/2021/015417A1 |
The present invention relates to a polycyclic aromatic derivative and an electroluminescent device comprising same. The electroluminescent device according to the present invention comprises a polycyclic aromatic derivative as a dopant c...
|
|
WO/2021/014380A1 |
Disclosed are compounds of formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions comprising the same, and methods of treating cancer or a respiratory inflammatory disease using the same: (I) wherein R1 is...
|
